

DAFTAR PUSTAKA

1. Kumar V, Abbas A, Aster J, Turner J. Robbins & Cotran Pathologic Basis of Disease Tenth Edition. Elsevier. 2021. 267–338 p.
2. DeVita VT, Lawrence TS, Rosenberg SA. Cancer: Principle and Practice of Oncology. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th ed. 2018. 1117–1156 p.
3. Ferlay J, Ervik M, Laversanne M, Colombet M, Mery L, Piñeros M, et al. International Agency for Research on Cancer WHO [Internet]. 2024 [cited 2025 Feb 18]. Global Cancer Observatory: Cancer Today. Available from: <https://gco.iarc.who.int/today>
4. Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI. Laporan Nasional Riset Kesehatan Dasar (Riskesdas) 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI; 2018.
5. Laporan Rumah Sakit Umum Pusat Dr. M. Djamil [Internet]. Padang; 2020 [cited 2025 May 15]. Report. Available from: <https://rsdjamil.co.id/laporan-rumah-sakit/>
6. Yang Y, Jiang X, Liu Y, Huang H, Xiong Y, Xiao H, et al. Elevated tumor markers for monitoring tumor response to immunotherapy. *EClinicalMedicine*. 2022 Apr 1;46. doi:10.1016/j.eclinm.2022.101381
7. Uygur MM, Gümüş M. The utility of serum tumor markers CEA and CA 15–3 for breast cancer prognosis and their association with clinicopathological parameters. *Cancer Treat Res Commun*. 2021;28:100402. doi:10.1016/j.ctarc.2021.100402
8. Schröder L, Mallmann MR, Domroese CM, Wefers N, Dolscheid-Pommerich R, Stoffel-Wagner B, et al. Method Comparison and Clinical Performance of Breast Cancer Tumor Markers on Novel Multiplex Immunoassay and Automatized LOCI Technology Platforms. *Diagnostics*. 2023 Sep 30;13(19):3101. doi:10.3390/diagnostics13193101
9. Momenimovahed Z, Mazidimoradi A, Allahqoli L, Khalajinia Z, Salehiniya H, Alkatout I. Utility of CA-125 for diagnosis and prognosis of breast cancer: a systematic review. *Explor Target Antitumor Ther*. 2025 May 15;6. doi:10.37349/etat.2025.1002316
10. Sjamsuhidajat, Jong D. Buku Ajar Ilmu Bedah 4th ed. Penerbit Buku Kedokteran EGC. 2017. p. 195.
11. Ryu JM, Kang D, Cho J, Lee JE, Kim SW, Nam SJ, et al. Prognostic Impact of Elevation of Cancer Antigen 15-3 (CA15-3) in Patients With Early Breast

- Cancer With Normal Serum CA15-3 Level. *J Breast Cancer*. 2023;26(2):126. doi:10.4048/jbc.2023.26.e17
12. Sabiston D. *Text Book of Surgery: The Biological Basis of Modern Surgical Practice*. 21st ed. Townsend CM, editor. Elsevier; 2021. 339–340 p.
 13. Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023. *Journal of the National Comprehensive Cancer Network*. 2023 Jun;21(6):594–608. doi:10.6004/jnccn.2023.0031
 14. American Cancer Society [Internet]. 2023 [cited 2025 Apr 22]. Understanding Recurrence. Available from: <https://www.cancer.org/cancer/survivorship/long-term-health-concerns/recurrence.html>
 15. Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. *Cell*. 2023 Apr;186(8):1708–28. doi:10.1016/j.cell.2023.01.040
 16. Eveline K, Purwanto H, Lestari P. Faktor Klinis dan Histopatologi serta Hubungannya dengan Kekambuhan Pascaoperasi pada Pasien Kanker Payudara di RSUD Dr. Soetomo, Januari–Juni 2015. *Indonesian Journal of Cancer*. 2017 Oct 11;11(2):55. doi:10.33371/ijoc.v11i2.502
 17. Ayuza M, Harahap WA, Rustam R, Nindrea RD. Faktor yang Berpengaruh Terhadap Disease Free Survival dan Overall Survival pada Pasien Kanker Payudara Usia Muda di Kota Padang Tahun 2008 - 2018. *Jurnal Kesehatan Andalas*. 2020 Jan 14;9(1S). doi:10.25077/jka.v9i1S.1157
 18. Chandradewi MR, Manuaba IBTW, Adiputra PAT. Faktor Yang Mempengaruhi Rekurensi Pada Pasien Kanker Payudara Pasca Modified Radical Mastectomy di RSUP Prof. Dr. I G.N.G Ngoerah. *Intisari Sains Medis*. 2022 Dec 7;13(3):690–3. doi:10.15562/ism.v13i3.1544
 19. Nolan L, Davey MG, Calpin GG, Ryan EJ, Boland MR. Risk of locoregional recurrence after breast cancer surgery by molecular subtype—a systematic review and network meta-analysis. *Irish Journal of Medical Science (1971 -)*. 2024 Dec 27;193(6):2965–74. doi:10.1007/s11845-024-03809-z
 20. Łukasiewicz S, Czezelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. *Cancers (Basel)*. 2021 Aug 25;13(17):4287. doi:10.3390/cancers13174287
 21. National Cancer Institute. 2020. Recurrent Cancer: When Cancer Comes back.

22. Lori J. Sokoll, Daniel W. Chan. Chapter 44 - Tumor markers. *Contemporary Practice in Clinical Chemistry*. INC; 2020. 779–793 p.
23. Tiwari M. Tumor Marker & Carcinogenesis. In: *Tumor Marker and Carcinogenesis*. River Publishers; 2022. p. 29–40. doi:10.1201/9781003357148-6
24. Rifai N. *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics*. 6th ed. In: Horvarth AR, Wittwer C, editors. St. Louis, Missouri: Elsevier; 2018. p. 617–23.
25. Trapani D, Siqueira M, Sengar M, Lombe DC. Prostate cancer: Burden, epidemiology and priority interventions. In: *Noncommunicable Diseases: A Compendium*. Taylor and Francis; 2023. p. 112–7. doi:10.4324/9781003306689-17
26. Fakhari A, Gharepapagh E, Dabiri S, Gilani N. Correlation of cancer antigen 15-3 (CA15-3) serum level and bony metastases in breast cancer patients. *Med J Islam Repub Iran*. 2019;33:142. doi:10.34171/mjiri.33.142 PubMed PMID: 32280648.
27. Varki A, Cummings RD, Esko JD, Stanley P. *Essentials of Glycobiology*. 4th ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2022. PubMed PMID: 35536922.
28. Chen W, Zhang Z, Zhang S, Zhu P, Ko JKS, Yung KKL. Muc1: Structure, function, and clinic application in epithelial cancers. *International Journal of Molecular Sciences*. MDPI; 2021. doi:10.3390/ijms22126567 PubMed PMID: 34207342.
29. Gao T, Cen Q, Lei H. A review on development of MUC1-based cancer vaccine. *Biomedicine & Pharmacotherapy*. 2020 Dec;132:110888. doi:10.1016/j.biopha.2020.110888
30. Apostolopoulos V, Stojanovska L, Gargosky SE. MUC1 (CD227): a multi-tasked molecule. *Cellular and Molecular Life Sciences*. 2015 Dec 21;72(23):4475–500. doi:10.1007/s00018-015-2014-z
31. Beckwith DM, Cudic M. Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design. *Semin Immunol*. 2020 Feb;47:101389. doi:10.1016/j.smim.2020.101389
32. Hing JX, Mok CW, Tan PT, Sudhakar SS, Seah CM, Lee WP, et al. Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance. *The Breast*. 2020 Aug;52:95–101. doi:10.1016/j.breast.2020.05.005

33. Yazdani A, Haghghat S. Determining Prognostic Factors of Disease-Free Survival in Breast Cancer Using Censored Quantile Regression. *Breast Cancer (Auckl)*. 2022;16. doi:10.1177/11782234221108058
34. Yoo YC, Park S, Kim HJ, Jung HE, Kim JY, Kim MH. Preoperative routine laboratory markers for predicting postoperative recurrence and death in patients with breast cancer. *J Clin Med*. 2021 Jun 2;10(12). doi:10.3390/jcm10122610
35. Hoti A, Gashi E, Kraja F, Sallaku A. Association of carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA 15-3) with socio-demographic factors and metastases site in women with metastatic breast cancer in Albania. *South East Eur J Public Health*. 2023 Jan 24. doi:10.56801/seejph.vi.116
36. M FR, Rikarni R, Harminarti N. Hubungan Kadar Cancer Antigen 15-3 Serum dengan Metastasis Kanker Payudara. *Jurnal Ilmu Kesehatan Indonesia*. 2021 May 24;1(3):371–8. doi:10.25077/jikesi.v1i3.110
37. Jahidin W, Irfani FN, Widyantara AB. Nilai Tumor Marker CA 15-3 dan Kadar Leukosit pada Penderita Kanker Payudara yang Menjalani Kemoterapi. *Jurnal Analis Kesehatan*. 2024 Jun;13(1).
38. Rifai N. *Tietz Textbook of Laboratory Medicine*. 7th ed. Elsevier Health Sciences; 2022. 351 p.
39. Budijono R. Korelasi antara nilai tumor marker CA 15-3 dan CEA terhadap grading histopatologi, metastasis, disease free survival, dan overall survival pada wanita penderita kanker payudara. Universitas Hasanuddin; 2020.
40. Pankotai-Bodó G, Oláh-Németh O, Sükösd F, Pankotai T. Routine molecular applications and recent advances in breast cancer diagnostics. *J Biotechnol*. 2024 Jan;380:20–8. doi:10.1016/j.jbiotec.2023.12.005
41. Yin L, Duan JJ, Bian XW, Yu S. Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Research*. 2020 Dec 9;22(1):61. doi:10.1186/s13058-020-01296-5
42. Madej-Czerwonka B, Korga-Plewko A, Czerwonka M. Modern breast cancer diagnostic methods. *Current Issues in Pharmacy and Medical Sciences*. 2022 Jul 1;35(1):1–5. doi:10.2478/cipms-2022-0001
43. Pereira R de O, da Luz LA, Chagas DC, Amorim JR, Nery-Júnior E de J, Alves ACBR, et al. Evaluation of the accuracy of mammography, ultrasound and magnetic resonance imaging in suspect breast lesions. *Clinics*. 2020;75. doi:10.6061/clinics/2020/e1805

44. Lawson MB, Partridge SC, Hippe DS, Rahbar H, Lam DL, Lee CI, et al. Comparative Performance of Contrast-enhanced Mammography, Abbreviated Breast MRI, and Standard Breast MRI for Breast Cancer Screening. *Radiology*. 2023 Aug 1;308(2). doi:10.1148/radiol.230576
45. Sharma S, Vicenty-Latorre FG, Elsherif S, Sharma S. Role of MRI in Breast Cancer Staging: A Case-Based Review. *Cureus*. 2021 Dec 27. doi:10.7759/cureus.20752
46. Wu HJ, Chu PY. Current and Developing Liquid Biopsy Techniques for Breast Cancer. *Cancers*. MDPI; 2022. doi:10.3390/cancers14092052
47. Freitas AJA de, Causin RL, Varuzza MB, Calfa S, Hidalgo Filho CMT, Komoto TT, et al. Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer. *International Journal of Molecular Sciences*. MDPI; 2022. doi:10.3390/ijms23179952 PubMed PMID: 36077348.
48. Tay TKY, Tan PH. Liquid biopsy in breast cancer: A focused review. *Archives of Pathology and Laboratory Medicine*. College of American Pathologists; 2021. p. 678–86. doi:10.5858/arpa.2019-0559-RA PubMed PMID: 32045277.
49. Luo J, Xiao J, Yang Y, Chen G, Hu D, Zeng J. Strategies for five tumour markers in the screening and diagnosis of female breast cancer. *Front Oncol*. 2023 Jan 23;12. doi:10.3389/fonc.2022.1055855
50. Luan Y, Wei J, Wang K, Cai D, Luo X, Fan W, et al. Comparison of the diagnostic performances of circulating tumor cells and the serum tumor markers CEA, CA125, and CA15-3 for breast cancer: A retrospective case-control study. *J BioX Res*. 2021 Jun 16;4(2):60–6. doi:10.1097/JBR.0000000000000093
51. Sajjadnia Z, Khayami R, Moosavi MR. Preprocessing Breast Cancer Data to Improve the Data Quality, Diagnosis Procedure, and Medical Care Services. *Cancer Inform*. 2020 Jan 27;19. doi:10.1177/1176935120917955
52. de Munck L, Eijkelboom AH, Otten JDM, Broeders MJM, Siesling S. Method of primary breast cancer detection and the disease-free interval, adjusting for lead time. *J Natl Cancer Inst*. 2024 Mar 1;116(3):370–8. doi:10.1093/jnci/djad230 PubMed PMID: 37935443.
53. Oprean CM, Hoinoiu T, Badau LM, Vidra R, Dragomir T, Dragomir GM, et al. Recurrence Patterns in Breast Cancer: A Single-Center Retrospective Analysis. *J Clin Med*. 2025 Nov 20;14(22):8243. doi:10.3390/jcm14228243
54. Bick U, Helbich TH. Follow-Up of Patients with Breast Cancer: Imaging of Local Recurrence and Distant Metastases. In. 2019. p. 167–78. doi:10.1007/978-3-030-11149-6_14 PubMed PMID: 32096934.

55. Fernández-Abad M, Caniego-Casas T, Carretero-Barrio I, Calderay-Domínguez M, Saavedra C, Hardisson D, et al. Ipsilateral Breast Carcinoma Recurrence. *American Journal of Surgical Pathology*. 2025 Mar;49(3):294–302. doi:10.1097/PAS.0000000000002351
56. Van Alsten SC, Zipple I, Calhoun BC, Troester MA. Misclassification of second primary and recurrent breast cancer in the surveillance epidemiology and end results registry. *Cancer Causes & Control*. 2025 Apr 19;36(4):421–32. doi:10.1007/s10552-024-01944-7
57. Boaitey GA, Martini R, Stonaker B, Bonsu EO, Adjei E, Kyei I, et al. Patterns of breast cancer locoregional relapse, metastasis, and subtypes in Ghana. *BMC Cancer*. 2024 Dec 2;24(1):1485. doi:10.1186/s12885-024-13254-x
58. Ke G, Muttath G, Yahia N, Ca S, Bharathan RK, Kumar A. Oncology and Radiotherapy © A study on pattern of locoregional recurrence and its relation to the irradiated volume in patients with carcinoma breast receiving adjuvant radiotherapy. *Oncology and Radioteraphy*. 2021;15(11).
59. Nolan L, Huan H, McDonnell W, Walsh S, Lowery A. The impact of mammographic breast density on locoregional recurrence in breast cancer: a systematic review and meta-analysis. *Breast Cancer Res Treat*. 2025 Aug 25. doi:10.1007/s10549-025-07804-5
60. Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. *Br J Cancer*. 2021 Jan 5;124(1):13–26. doi:10.1038/s41416-020-01161-4
61. Courtney D, Davey MG, Moloney BM, Barry MK, Sweeney K, McLaughlin RP, et al. Breast cancer recurrence: factors impacting occurrence and survival. *Ir J Med Sci*. 2022;191(6). doi:10.1007/s11845-022-02926-x
62. Tsai CH, Hsieh HF, Lai TW, Kung PT, Kuo WY, Tsai WC. Effect of multidisciplinary team care on the risk of recurrence in breast cancer patients: A national matched cohort study. *The Breast*. 2020 Oct;53:68–76. doi:10.1016/j.breast.2020.07.001
63. Montagna G, Gupta H V., Hannum M, Tan KS, Lee J, Scarpa JR, et al. Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer. *Br J Anaesth*. 2021 Feb 1;126(2):367–76. doi:10.1016/j.bja.2020.10.021 PubMed PMID: 33220939.
64. Cathcart-Rake EJ, Ruddy KJ, Bleyer A, Johnson RH. Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years. *JCO Oncol Pract*. 2021 Jun;17(6):305–13. doi:10.1200/op.20.00793 PubMed PMID: 33449828.

65. Andrianto A, Sudiana IK, Suprabawati DGA, Notobroto HB. Immune system and tumor microenvironment in early-stage breast cancer: different mechanisms for early recurrence after mastectomy and chemotherapy on ductal and lobular types. *F1000Res.* 2023;12. doi:10.12688/f1000research.134302.2 PubMed PMID: 38046195.
66. Roy M, Biswas J, Datta A. Genetics and Epigenetics of Breast Cancer. *Genetics and Epigenetics of Breast Cancer.* 2023. doi:10.1007/978-981-19-9925-3
67. Kumilau R, Hayati F, Liew JES, Sharif SZ, Sahid Nik Lah NA. Short term recurrence and survival rate of breast cancer patients post surgical treatment; north borneo experience. *Annals of Medicine & Surgery.* 2022 Sep;81. doi:10.1016/j.amsu.2022.104560
68. Amanta SZ. Faktor-Faktor yang Memengaruhi Disease Free Survival 5 Tahun Pasien Kanker Payudara di RSUD Raden Mattaher Jambi. Universitas Jambi; 2025.
69. Pedersen RN, Esen BÖ, Mellekjær L, Christiansen P, Ejlersen B, Lash TL, et al. The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis. *JNCI: Journal of the National Cancer Institute.* 2022 Mar 8;114(3):391–9. doi:10.1093/jnci/djab202
70. Matulesy RY, Purwanto H, Danardono E. Breast cancer subtypes and disease-free interval in earlystage breast cancer. *Eurasian J Biosci.* 2020;14(1):2539–44.
71. Mancini S, Bucchi L, Biggeri A, Giuliani O, Baldacchini F, Ravaioli A, et al. Incidence and temporal patterns of true recurrences and second primaries in women with breast cancer: A 10-year competing risk-adjusted analysis. *The Breast.* 2025 Apr;80:103883. doi:10.1016/j.breast.2025.103883
72. Tarighati E, Keivan H, Mahani H. A review of prognostic and predictive biomarkers in breast cancer. *Clinical and Experimental Medicine.* Springer Science and Business Media Deutschland GmbH; 2023. p. 1–16. doi:10.1007/s10238-021-00781-1 PubMed PMID: 35031885.
73. Ma YY, Wang H, Zhao WD, Li YF, Wang JJ, Chen XY, et al. Prognostic Value of Combined Lactate Dehydrogenase, C-Reactive Protein, Cancer Antigen 153 and Cancer Antigen 125 in Metastatic Breast Cancer. *Cancer Control.* 2022 Jan 3;29. doi:10.1177/10732748211053150 PubMed PMID: 34989251.
74. Dahlan MS. Besar Sampel dan Teknik Pengambilan Sampel Dalam Penelitian Kedokteran dan Kesehatan. 3rd ed. Jakarta: Salemba Medika; 2010. 46–59 p.

75. Rini Febrianti, Mugi Wahidin. Hubungan usia dan riwayat keluarga dengan kejadian kanker payudara di RSUP Dr. M. Djamil Padang tahun 2021. *Journal of Scientech Research and Development*. 2022 Feb 26;3(1):016–23. doi:10.56670/jsrd.v3i1.36
76. Teichgraeber DC, Guirguis MS, Whitman GJ. Breast Cancer Staging: Updates in the *AJCC Cancer Staging Manual*, 8th Edition, and Current Challenges for Radiologists, From the *AJR* Special Series on Cancer Staging. *American Journal of Roentgenology*. 2021 Aug;217(2):278–90. doi:10.2214/AJR.20.25223
77. Mochtar NM, Aisy LR, Irawati DN, Finansah YW. Hubungan Faktor Genetik dan Faktor Usia terhadap Kejadian Kanker Payudara pada Wanita di RSUD Dr. Soedomo Trenggalek Periode 2020-2021. *JurnalMU: Jurnal Medis Umum*. 2024 Dec 6;1(3):175–84. doi:10.30651/jmu.v1i3.24772
78. Rini Febrianti, Mugi Wahidin. Hubungan usia dan riwayat keluarga dengan kejadian kanker payudara di rsup dr m. Djamil padang tahun 2021. *Journal of Scientech Research and Development*. 2022 Feb 26;3(1):016–23. doi:10.56670/jsrd.v3i1.36
79. Danforth DN. Genomic changes in normal breast tissue in women at normal risk or at high risk for breast cancer. *Breast Cancer (Auckl)*. 2016 Aug 17;10:109–46. doi:10.4137/BCBCR.S39384
80. Helmi AF. Hubungan Subtipe Kanker Payudara dengan Kejadian Metastasis di RSUP Dr. M. Djamil Padang. [Padang]: Dr. M. Djamil General Hospital; 2021.
81. Paramita S, Raharjo EN, Niasari M, Azizah F, Hanifah NA. Luminal B is the Most Common Intrinsic Molecular Subtypes of Invasive Ductal Breast Carcinoma Patients in East Kalimantan, Indonesia. *Asian Pacific Journal of Cancer Prevention*. 2019 Aug 1;20(8):2247–52. doi:10.31557/APJCP.2019.20.8.2247
82. Rahmawati Y, Setyawati Y, Widodo I, Ghozali A, Purnomosari D. Molecular Subtypes of Indonesian Breast Carcinomas - Lack of Association with Patient Age and Tumor Size. *Asian Pacific Journal of Cancer Prevention*. 2018;19(1):161–6.
83. Fadhlillah MF, Hanum FJ. Hubungan Ekspresi ER, PR, HER2, Dan Ki-67 dengan Kejadian Rekurensi 2 Tahunan Pada Pasien Kanker Payudara Di Padang, Sumatera Barat . *Sinergi: Jurnal Riset Ilmiah*. 2025 Mar;2(3):1296–306.
84. Akbar OGK, Syahril E, Kurniawan A. A case report: residual breast Cancer post modified radical mastectomy with complete chemotherapy followed by

- adjuvant hormone therapy at Ibnu Sina Hospital. Prepotif: Jurnal Kesehatan Masyarakat. 2025 Aug 30;9(2):6833–40. doi:10.31004/prepotif.v9i2.49621
85. Abd. Mirsyad, Azis Beru Gani, Karim M, Raeny Purnamasari, Karsa NS, Andi Husni Tanra, et al. Hubungan Usia Pasien Dengan Tingkat Stadium Kanker Payudara Di RS Ibnu Sina Makassar 2018. *Fakumi Medical Journal: Jurnal Mahasiswa Kedokteran*. 2022 Feb 28;2(2):109–15. doi:10.33096/fmj.v2i2.48
86. Setiawan MRC. Faktor faktor yang memengaruhi terjadinya kekambuhan pada pasien kanker payudara triple negatif di RSUP Dr. M. Djamil Padang. [Padang]: Universitas Andalas; 2023.
87. Gupta SK, Kumar V, Anees A, Goel A. The study of prognostic significance of CA 15-3 in breast cancer. *International Surgery Journal*. 2018 Jan 25;5(2):580. doi:10.18203/2349-2902.isj20180356
88. Ito M, Amari M, Sato A, Hikichi M, Sakamoto A, Yamazaki A, et al. Risk factors for late recurrence and postrelapse survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative breast cancer after 5 years of endocrine therapy. *The Breast*. 2024 Feb;73:103604. doi:10.1016/j.breast.2023.103604
89. R. Al-Bayati M. Utility of CA 15-3 in diagnosis of Breast Cancer Recurrence. An Observational Study. *Al-Qadisiyah Medical Journal*. 2018 Dec 13;14(25):35–41. doi:10.28922/qmj.2018.14.25.35-41

